Literature DB >> 3816105

Evaluation of three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy.

B L Carter, J W Taylor, A Becker.   

Abstract

Three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy were evaluated. Adult inpatients who had received warfarin sodium 10 mg daily for less than three days were eligible for the study. After receiving their third warfarin dose, patients were randomly assigned to have their warfarin dosages adjusted using one of three dosage-prediction methods: by analog computer (n = 31), linear regression (n = 22), or empiric dosing by the physician (n = 34). A prothrombin time (PT) ratio (patient PT divided by control PT) between 1.3 and 2.5 was considered to be in the therapeutic range. For patients who achieved a stable PT ratio (defined as a PT ratio between 1.3 and 2.5 that varied by less than 0.05 on two consecutive days or by less than 0.1 on three consecutive days without a dosage change) before discharge, the number of days (time to stabilization) from administration of the first warfarin dose to achievement of the warfarin dosage that produced a stable PT ratio (stabilization dosage) was compared. A total of 54 patients met the study criteria for a stable PT ratio before hospital discharge (analog computer, n = 20; linear regression, n = 15; empiric dosing, n = 19). The mean times to stabilization were 6.8 days in the analog-computer group, 7.3 days in the linear-regression group, and 8.4 days in the empiric-dosing group; these times were not significantly different. All 20 stabilized patients in the analog-computer group achieved a stable PT ratio by the fourth dosage prediction.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3816105

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  8 in total

Review 1.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Control of warfarin therapy.

Authors:  D K Scott
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

3.  Warfarin dosage requirements: prospective clinical trial of a method for prediction from the response to a single dose.

Authors:  D M Jupe; G M Peterson; R L Coleman; S McLean
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

Review 4.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

5.  Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients.

Authors:  Andrew Frazer; James Rowland; Alison Mudge; Michael Barras; Jennifer Martin; Peter Donovan
Journal:  Eur J Clin Pharmacol       Date:  2019-09-11       Impact factor: 2.953

Review 6.  Long-term anticoagulation. Indications and management.

Authors:  B M Stults; W H Dere; T H Caine
Journal:  West J Med       Date:  1989-10

Review 7.  Computerized clinical decision support systems for acute care management: a decision-maker-researcher partnership systematic review of effects on process of care and patient outcomes.

Authors:  Navdeep Sahota; Rob Lloyd; Anita Ramakrishna; Jean A Mackay; Jeanette C Prorok; Lorraine Weise-Kelly; Tamara Navarro; Nancy L Wilczynski; R Brian Haynes
Journal:  Implement Sci       Date:  2011-08-03       Impact factor: 7.327

Review 8.  Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision-maker-researcher partnership systematic review.

Authors:  Robby Nieuwlaat; Stuart J Connolly; Jean A Mackay; Lorraine Weise-Kelly; Tamara Navarro; Nancy L Wilczynski; R Brian Haynes
Journal:  Implement Sci       Date:  2011-08-03       Impact factor: 7.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.